Ascendis Pharma A/S (NASDAQ:ASND) had its price target raised by analysts at Bank of America Corporation from $246.00 to $260.00. They now have a "buy" rating on the stock.
RBC Maintains Outperform Rating on Ascendis Pharma (ASND) Amid Growth Targets [Yahoo! Finance]
Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Ascendis Pharma A/S (NASDAQ:ASND) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Ascendis: Why I'm Skeptical On Takeover Rumors, Long-Term Targets [Seeking Alpha]